Publications by authors named "Stephan Linden"

Claim this Profile
C
Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain.
Juan E Megias-Vericat, Gines Escolar, Michele R Wilson, Pablo Mendez, Cheryl L McDade, Stephan Linden

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of empagliflozin in the treatment of Malaysian patients with chronic heart failure and preserved or mildly reduced ejection fraction.
Yi Jing Tan, Stephan Linden, Siew Chin Ong

PLoS One· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Empagliflozin cost-effectiveness analysis in Japanese heart failure with mildly reduced and preserved ejection fraction.
Hiroyuki Tsutsui, Hiroyuki Sakamaki, Shin-Ichi Momomura, Yasushi Sakata, Yutaro Kotobuki, Stephan Linden

ESC Heart Fail· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Empagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction in the United States.
Odette S Reifsnider, Ali Tafazzoli, Stephan Linden, Jack Ishak, Pal Rakonczai

J Am Heart Assoc· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.
Laurent Fauchier, Nicolas Lamblin, Jean Tardu, Lucile Bellier, Harinala Groyer, Stephan Linden

Pharmacoecon Open· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction.
Ali Tafazzoli, Odette S Reifsnider, Leana Bellanca, Jack Ishak, Marc Carrasco, Stephan Linden

Eur J Health Econ· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40.
Spyros Kolovos, Leana Bellanca, Harinala Groyer, Giuseppe M C Rosano, Alexandra Solé, Stephan Linden

ESC Heart Fail· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resource utilisation and outcomes of people with heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study.
Stephan Linden, Nicholas D Gollop, Ruth Farmer

Open Heart· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of empagliflozin in heart failure patients irrespective of ejection fraction in England.
Spyros Kolovos, Leana Bellanca, Harinala Groyer, Giuseppe Rosano, Jennifer Gaultney, Stephan Linden

J Cardiovasc Med (Hagerstown)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical Costs of Chronic Kidney Disease and Type 2 Diabetes Among Newly Diagnosed Heart Failure Patients With Reduced, Mildly Reduced, and Preserved Ejection Fraction.
Gregory A Nichols, Qing Qiao, Stephan Linden, Bettina J Kraus

Am J Cardiol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and prevalence of heart failure in England: a descriptive analysis of linked primary and secondary care data - the PULSE study.
Leana Bellanca, Stephan Linden, Ruth Farmer

BMC Cardiovasc Disord· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness analysis of empagliflozin in patients with heart failure with reduced ejection fraction in Japan based on the EMPEROR-Reduced trial.
Hiroyuki Tsutsui, Hiroyuki Sakamaki, Shin-Ichi Momomura, Yasushi Sakata, Yutaro Kotobuki, Stephan Linden

J Cardiol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of adding empagliflozin to the standard of care for patients with heart failure with reduced ejection fraction from the perspective of healthcare system in Malaysia.
Siew Chin Ong, Joo Zheng Low, Stephan Linden

Front Pharmacol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore.
Lijoy Varghese, Weiqin Lin, Stephan Linden, Ai Ling Lum, David Sim

Value Health Reg Issues· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medication Use for ADHD and the Risk of Driving Citations and Crashes Among Teenage Drivers: A Population-Based Cohort Study.
Almut G Winterstein, Yan Li, Tobias Gerhard, Stephan Linden, Jonathan J Shuster

J Atten Disord· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure.
Odette S Reifsnider, Anuraag R Kansal, Jennifer Franke, Joseph Lee, Jyothis T George, Stephan Linden

ESC Heart Fail· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comorbidities and relevant outcomes, commonly associated with cancer, of patients newly diagnosed with advanced non-small-cell lung cancer in Sweden.
Stephan Linden, Josefine Redig, Ana Banos Hernaez, Jonas Nilsson, Dorthee B Bartels

Eur J Cancer Care (Engl)· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Federico Cappuzzo, Ross Soo, Maximilian Hochmair, Martin Schuler, Kwok Chi Lam, Stephan Linden

Future Oncol· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study.
Tosha A Egelund, Sarah K Wassil, Elisa M Edwards, Stephan Linden, Jose E Irazuzta

Intensive Care Med· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study.
Almut G Winterstein, Tobias Gerhard, Paul Kubilis, Arwa Saidi, Stephan Linden

BMJ· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient counseling practices in U.S. pharmacies: effects of having pharmacists hand the medication to the patient and state regulations on pharmacist counseling.
Carole L Kimberlin, Allison Newland Jamison, Stephan Linden, Almut G Winterstein

J Am Pharm Assoc (2003)· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of consumer medication information dispensed in retail pharmacies.
Almut G Winterstein, Stephan Linden, Abigail E Lee, Erica M Fernandez, Carole L Kimberlin

Arch Intern Med· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis